CEPRAVIN PREVENTS FLARE UPS OF CLINICAL MASTITIS THROUGHOUT THE DRY PERIOD
This is especially important if it is not possible to observe the cows closely. Cepravin has been shown in New Zealand to reduce the incidence of dry period mastitis from 12.3% to 1.2% during the dry period and at calving.4
It was in this trial that Cepravin, the long-acting DCT used, was shown to hasten the formation of the keratin plug in the teat canal. This effect has not been shown with other DCTs.
The results from the Williamson trial have been duplicated in a number of other trials both here and overseas.5,15,16
In a comparative trial in Waikato,8 animals treated with Cepravin were 20 times less likely to get clinical mastitis than the controls during the dry period. Cows treated with Bovaclox were five times less likely to get clinical mastitis than controls during the dry period.
Williamson J.H. et al. (1995). The prophylactic effect of a dry-cow antibiotic against Streptococcus uberis. NZVJ.
Woolford M. W. et al. (1998). The prophylactic effect of a teat sealer on bovine mastitis during the dry period and the following lactation. NZVJ.
McKay B. (1998, 1999). MSD Animal Health data on file
McDougall et al. (2011). A randomised, non-inferiority trial of a new cephalonium dry-cow therapy. NZVJ.
Berry and Hillerton (2002). The effect of selective dry cow treatment on new intramammary infections. J Dairy Sci.